Bortezomib will raise the stage or effect of flibanserin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of. Amplified flibanserin adverse outcomes may arise if coadministered with multiple weak CYP3A4 inhibitors. Drug Formulary facts is intended to be used by Health care specialists. It is far from intended to https://aloisd333qcm6.theobloggers.com/profile